Segment Information

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segment Information

Segment Information

We operate as one operating segment, which is discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.

Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.

Revenue by product is summarized as follows:

	For the Years Ended December 31,
	2016						2015						2014
(In millions)	United States		Rest of World		Total		United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis (MS):
TECFIDERA	$	3,169.4	$	798.7	$	3,968.1	$	2,908.2	$	730.2	$	3,638.4	$	2,426.6	$	482.6	$	2,909.2
AVONEX	1,675.3		638.2		2,313.5		1,790.2		840.0		2,630.2		1,956.7		1,056.4		3,013.1
PLEGRIDY	305.0		176.7		481.7		227.1		111.4		338.5		27.8		16.7		44.5
TYSABRI	1,182.9		780.9		1,963.8		1,103.1		783.0		1,886.1		1,025.1		934.4		1,959.5
FAMPYRA	—		84.9		84.9		—		89.7		89.7		—		80.2		80.2
ZINBRYTA	—		7.8		7.8		—		—		—		—		—		—
Hemophilia:
ELOCTATE	445.2		68.0		513.2		308.3		11.4		319.7		58.4		—		58.4
ALPROLIX	268.0		65.7		333.7		208.9		25.6		234.5		72.1		3.9		76.0
Other product revenues:
FUMADERM	—		45.9		45.9		—		51.4		51.4		—		62.5		62.5
SPINRAZA	4.6		—		4.6		—		—		—		—		—		—
BENEPALI	—		100.6		100.6		—		—		—		—		—		—
FLIXABI	—		0.1		0.1		—		—		—		—		—		—
Total product revenues	$	7,050.4	$	2,767.5	$	9,817.9	$	6,545.8	$	2,642.7	$	9,188.5	$	5,566.7	$	2,636.7	$	8,203.4

Geographic Information

The following tables contain certain financial information by geographic area:

December 31, 2016 (In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenues from external customers	$	7,050.4	$	1,533.5	$	703.7	$	217.3	$	313.0	$	9,817.9
Revenues from anti-CD20 therapeutic programs	$	1,249.5	$	1.9	$	—	$	—	$	63.1	$	1,314.5
Other revenues from external customers	$	224.7	$	70.0	$	1.5	$	20.2	$	—	$	316.4
Long-lived assets	$	1,272.3	$	1,219.3	$	1.8	$	7.0	$	1.4	$	2,501.8
December 31, 2015 (In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenues from external customers	$	6,545.8	$	1,497.6	$	668.1	$	143.7	$	333.3	$	9,188.5
Revenues from anti-CD20 therapeutic programs	$	1,269.8	$	3.5	$	—	$	—	$	65.9	$	1,339.2
Other revenues from external customers	$	142.0	$	29.6	$	1.6	$	62.9	$	—	$	236.1
Long-lived assets	$	1,296.5	$	879.4	$	2.3	$	7.7	$	1.7	$	2,187.6
December 31, 2014 (In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenues from external customers	$	5,566.7	$	1,383.9	$	811.8	$	112.8	$	328.2	$	8,203.4
Revenues from anti-CD20 therapeutic programs	$	1,117.1	$	7.7	$	—	$	—	$	70.6	$	1,195.4
Other revenues from external customers	$	212.6	$	31.6	$	1.8	$	58.5	$	—	$	304.5
Long-lived assets	$	1,055.5	$	701.9	$	2.5	$	2.6	$	3.2	$	1,765.7

(1) Represents amounts related to Europe less those attributable to Germany.

Revenues from Anti-CD20 Therapeutic Programs

Approximately 11%, 12% and 12% of our total revenues in 2016, 2015 and 2014, respectively, are derived from our collaboration agreement with Genentech. For additional information related to our collaboration with Genentech, please read Note 19, Collaborative and Other Relationships to these consolidated financial statements.

Significant Customers

We recorded revenue from two wholesalers accounting for 35% and 22% of gross product revenues in 2016, 34% and 26% of gross product revenues in 2015, and 33% and 27% of gross product revenues in 2014, respectively.

Other

As of December 31, 2016, 2015 and 2014, approximately $643.6 million, $684.9 million and $676.0 million, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark.

As of December 31, 2016 and 2015, approximately $545.5 million and $161.5 million, respectively, of our long-lived assets were related to the construction of a biologics manufacturing facility in Solothurn, Switzerland.

For additional information related to our manufacturing facility in Solothurn, Switzerland, please read Note 10, Property, plant and equipment to these consolidated financial statements.